[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"icg-indocyanine-green\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:icg-indocyanine-green":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,77,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100646291","phase-2-shuganhuazhuo-formula-for-advanced-hepatocellular-carcinoma-with-damp-heat-syndrome-100646291",false,"NCT07691645","Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome","Shuganhuazhuo Formula (Chinese Herbal Medicine) in the Combined Treatment of Advanced Hepatocellular Carcinoma With Damp-Heat and Blood Stasis Syndrome: An Open-Label Randomized Controlled Trial","DAWNbreak-120","Inclusion Criteria:\n\n1. According to the National Health Commission(China)'s \"Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2026)\", clinically or pathologically diagnosed as primary liver cancer.\n2. Barcelona Clinic Liver Cancer (BCLC) stage is C.\n3. Planning to receive second-line or third-line anti-tumor therapies.\n4. The dominant syndrome in traditional Chinese medicine diagnosis is damp or heat.\n5. Age: ≥ 18 years and ≤ 75 years.\n\nExclusion Criteria:\n\n1. Expected survival is less than 3 months.\n2. Definitive pathological diagnosis of intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma (cHCC-CCA).\n3. Comorbid severe heart, liver, kidney dysfunction:\n\n   1. heart\n\n      * New York Heart Association(NYHA) cardiac function \\> class II\n   2. liver\n\n      * aspartate aminotransferase \\> 3 times the upper limit of normal\n      * alanine aminotransferase \\> 3 times the upper limit of normal\n      * bilirubin \\> 3 times the upper limit of normal\n   3. kidney\n\n      * creatinine clearance (Cockcroft-Gault) \\\u003C 60 mL\u002Fmin)\n4. Concurrent with other malignant tumors.","ALL","18 Years","75 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases. Under the current targeted and immunotherapy-based treatment approaches, the overall survival of patients with advanced HCC has improved significantly compared to targeted therapy alone. However, there are still limitations in therapeutic effectiveness. In addition to the tumor burden, liver reserve function is associated with the prognosis of HCC. Cirrhosis, tumor burden, and anti-tumor treatment can all lead to damage to liver reserve function, which in turn leads to a decrease in patient survival. Currently, there are no specific treatments for deteriorating liver reserve function; only symptomatic treatments such as reducing transaminase levels, bilirubin levels, and blood ammonia levels, as well as diuretics, are available. The indocyanine green(ICG) clearance test allows for precise, dynamic, and quantitative measurement of liver clearance function, making it a commonly used method for assessing liver reserve function in clinical practice.Previous studies have confirmed that its test results are closely related to the prognosis of HCC.\n\nShuganhuazhuo Formula(SHF) is a Chinese herbal medicine used to treat advanced HCC with syndrome of Damp-Heat and Blood stasis. It can inhibit necrosis in the livers of mice in experimental models, reduce fibrosis scores, and demonstrate potential therapeutic effects in protecting the liver, reducing oxidative stress, and preventing fibrosis.\n\nThis study is an open-label randomized controlled trial. Patients with advanced HCC who are receiving second-line or third-line anti-tumor treatment are randomly assigned in a 1:1 ratio to either the control group or the traditional Chinese medicine (TCM) group. The control group receives anti-tumor treatment as recommended by guidelines, while the TCM group receives additional treatment with SHF. SHF involves decocting traditional Chinese medicine ingredients twice daily. Each time, 150 ml of the decoction is prepared and taken orally half an hour after breakfast and dinner. Treatment lasts for 6 months. During this period, the ICG clearance test is performed every 2 months to assess liver reserve function, and quality of life is also evaluated. After the treatment period, follow-ups on survival and safety are conducted every 3 months. This study aims to evaluate the benefits of the SHF in terms of liver reserve function, overall survival, and quality of life in patients with HCC of the syndrome of Damp-Heat and Blood stasis. It also includes exploratory analyses of differences in biomarker expression during treatment.",[28,29,30,31,32],"HCC - Hepatocellular Carcinoma","Chinese Herbal Medicine","ICG (Indocyanine Green)","Overall Survival (All-cause Mortality)","Quality of Life",[34,35,36,37,38,39],"Hepatocellular Carcinoma(HCC)","Chinese herbal medicine","Shuganhuazhuo Formula(SHF)","Liver reserve function","Overall survival","Quality of life","NOT_YET_RECRUITING","2026-07-08",{"date":43,"type":44},"2026-07-09","ACTUAL",{"date":46,"type":22},"2026-09-01",{"date":48,"type":22},"2031-08-31",{"name":50,"class":51},"Xiang-Qian","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100643098","icg-in-colon-cancer-100643098","NCT07638956","ICG in Colon Cancer","A Prospective Study of Indocyanine Green (ICG) Fluorescence-Guided Lymphatic Mapping During Laparoscopic Colon Cancer Resection","ICG","Inclusion Criteria:\n\nAge \\>= 18 years.\n\n\\- Histologically confirmed colon adenocarcinoma.\n\nExclusion Criteria:\n\n* Emergency surgery (obstruction\u002Fperforation with sepsis) requiring urgent operation.\n* Known allergy or contraindication to ICG (including prior anaphylaxis to ICG; severe hypersensitivity history per anesthesia assessment).\n* Pregnancy or breastfeeding.\n* Severe hepatic failure (because ICG clearance is hepatobiliary) or other contraindication determined by anesthesia team.\n* Planned palliative resection only.\n* ASA physical status IV or patients otherwise deemed unfit for elective curative colectomy.",{"count":62,"type":22},25,[64],"NA","The aim of this study is to evaluate the role of indocyanine green (ICG) injection in fluorescence-guided lymphatic mapping during laparoscopic colon cancer resection. This is a single-center prospective single-arm pilot clinical study that will include at least 25 patients with resectable colon cancer. All enrolled patients will undergo intraoperative subserosal ICG-guided lymphatic mapping before dissection, and intravenous ICG perfusion assessment before anastomosis. The primary goal is to determine the proportion of analyzable pN+ patients in whom all metastatic lymph nodes identified on final histopathology are located within the ICG-mapped lymphatic basin.",[67,30],"Colon Cancer","2026-06-10",{"date":70,"type":44},"2026-06-12",{"date":72,"type":22},"2026-06-01",{"date":74,"type":22},"2028-11-01",{"name":76,"class":51},"Tanta University",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":52},"100624221","phase-3-the-value-of-near-infrared-fluorescence-imaging-in-the-protection-of-the-recurrent-laryngeal-nerve-during-minimally-invasive-esophagectomy-100624221","NCT07406815","The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy","The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy：A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years at the time of diagnosis (excluding 18 and 75);\n* Preoperative biopsy pathology confirming esophageal cancer;\n* Undergoing elective thoracoscopic esophageal cancer radical surgery with intraoperative anastomosis;\n* Tolerable heart, lung, liver, and kidney function for surgery;\n* Patients and their families are able to understand and willing to participate in this clinical study, and have signed an informed consent form.\n\nExclusion Criteria:\n\n* Allergy to ICG or iodine;\n* History of neck or thoracic surgery;\n* Patients requiring emergency surgery;\n* Tumors involving adjacent organs necessitating combined organ resection;\n* Patients with tumor recurrence or distant metastasis;\n* Participation in or having participated in other clinical trials within 4 weeks prior to selection;\n* History of severe mental illness;\n* Pregnant or lactating women;\n* Patients with other conditions deemed unsuitable for participation by the investigator;\n* Intraoperative conversion to open thoracotomy.\n* Patients who, after assessment or intraoperative exploration, cannot undergo the planned surgery;\n* Patients who voluntarily withdraw from the study;\n* Patients with concomitant non-neoplastic conditions that prevent them from continuing with the study protocol;\n* Patients who, after enrollment in the study, are unable to complete it due to other reasons.",{"count":85,"type":22},144,[87],"PHASE3","The goal of this clinical trial is to learn whether the application of indocyanine green near-infrared imaging system can accurately locate the recurrent laryngeal nerve (RLN) during lymph node dissection in esophageal cancer radical surgery, thereby reducing the risk of RLN injury. The main questions it aims to answer are:\n\n1. Can preoperative intravenous administration of indocyanine green enable visualization of the RLN;\n2. Does performing RLN dissection guided by near-infrared imaging system reduce the probability of RLN injury, leading to better clearance of RLN lymph nodes and improved RLN protection rates? Researchers will compare whether indocyanine green was intravenously administered preoperatively to assess intraoperative RLN visualization. Participants in the study group will receive intravenous indocyanine green at a dose of 5mg\u002Fkg 24 hours before surgery. All patients will be monitored for RLN injury-related complications postoperatively, and RLN injury status will be objectively assessed via laryngoscopy one week post-operation.",[90,91,30,92],"Esophageal Cancer","Recurrent Laryngeal Nerve","Lymph Node Dissection","2026-02-05",{"date":95,"type":44},"2026-02-12",{"date":72,"type":22},{"date":98,"type":22},"2028-06-01",{"name":100,"class":51},"Fujian Medical University Union Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":108,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":119,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":52},"100576089","phase-2-photo-medicine-guided-dual-approach-for-reoperation-of-sentinel-lymph-nodes-in-locally-recurrent-breast-cancer-patients-100576089","NCT06780748","Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients","Inclusion Criteria:\n\n* Patients with ipsilateral locally recurrent breast cancer who previously underwent ipsilateral axillary surgery.\n* Female patients aged 18 years or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Patients who voluntarily decide to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with distant metastases.\n* Patients who previously underwent ipsilateral mastectomy.\n* Pregnant or breastfeeding women.\n* Patients with a general condition that impairs the ability to understand or provide informed consent.",true,"FEMALE",{"count":110,"type":22},30,[25],"Sentinel lymph node biopsy (SLNB) is essential for staging and treatment planning in early breast cancer patients. As a less invasive procedure, it has replaced axillary lymph node dissection (ALND) by reducing complications and improving patient outcomes. However, the 10-year local recurrence rate for breast cancer is approximately 2-10%, and the role of SLNB in the surgical management of recurrent breast cancer remains unclear.\n\nAccording to the NCCN guidelines and Korean Breast Cancer Treatment Recommendations, surgical management for recurrent breast cancer includes mastectomy and axillary lymph node surgery for patients who have previously undergone breast-conserving surgery and radiotherapy. For axillary recurrence, surgery is recommended if feasible, followed by radiotherapy. Conversely, the ASCO guidelines recommend SLNB for surgically resectable recurrent breast cancer, and recent studies have reported promising outcomes for repeat sentinel lymph node biopsy (reSLNB). Vugts G et al. demonstrated an 80.1% tumor-negative rate with reSLNB, suggesting that ALND could be avoided in many cases.\n\nAlthough reSLNB offers the advantage of reducing unnecessary invasive procedures and associated complications, challenges remain due to disrupted lymphatic pathways in patients who have previously undergone surgery and radiotherapy. Additionally, research on the long-term prognosis of these patients is still limited.\n\nThis study aims to evaluate the detection rate of sentinel lymph nodes using a photo-medicine-based dual localization technique that combines traditional radiotracer methods with indocyanine green-fluorescence (ICG-F) in patients undergoing reSLNB for locally recurrent breast cancer.",[114,115,116,117,118],"Breast Cancer","Locally Recurrent Breast Cancer","Sentinel Lymph Node Biopsy (SLNB)","Reoperation","ICG (indocyanine Green)",[120,121,116,117,122],"Breast cancer","Locally Recurrent Breast cancer","ICG(indocyanine green)","RECRUITING","2025-01-13",{"date":126,"type":44},"2025-01-17",{"date":128,"type":44},"2023-08-13",{"date":130,"type":22},"2025-12-31",{"name":132,"class":133},"National Cancer Center, Korea","OTHER_GOV"]